
USD
+$0.00
(+0.00%
)At Close (As of Dec 3, 2025)
$289.24M
Market Cap
-
P/E Ratio
-1.25
EPS
$8.85
52 Week High
$4.76
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $40M |
| Total Revenue | $129M |
| Cost Of Revenue | $89M |
| Costof Goods And Services Sold | $89M |
| Operating Income | -$17M |
| Selling General And Administrative | $44M |
| Research And Development | $8.3M |
| Operating Expenses | $58M |
| Investment Income Net | - |
| Net Interest Income | -$22M |
| Interest Income | - |
| Interest Expense | $22M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8M |
| Income Before Tax | -$39M |
| Income Tax Expense | $43K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$39M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$17M |
| Ebitda | -$8.8M |
| Net Income | -$39M |
| Field | Value (USD) |
|---|---|
| Total Assets | $239M |
| Total Current Assets | $86M |
| Cash And Cash Equivalents At Carrying Value | $8.3M |
| Cash And Short Term Investments | $8.3M |
| Inventory | $32M |
| Current Net Receivables | $44M |
| Total Non Current Assets | $154M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $4.2M |
| Intangible Assets Excluding Goodwill | $4.2M |
| Goodwill | $14M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $1.5M |
| Other Non Current Assets | - |
| Total Liabilities | $238M |
| Total Current Liabilities | $30M |
| Current Accounts Payable | $8.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $3.8M |
| Total Non Current Liabilities | $208M |
| Capital Lease Obligations | $387K |
| Long Term Debt | $127M |
| Current Long Term Debt | $3.4M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $131M |
| Other Current Liabilities | $15M |
| Other Non Current Liabilities | $9.7M |
| Total Shareholder Equity | $1.3M |
| Treasury Stock | - |
| Retained Earnings | -$205M |
| Common Stock | $37K |
| Common Stock Shares Outstanding | $35M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$206K |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $8M |
| Capital Expenditures | $13M |
| Change In Receivables | - |
| Change In Inventory | $7.7M |
| Profit Loss | - |
| Cashflow From Investment | -$6.4M |
| Cashflow From Financing | $6.4M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$39M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $40M |
| Total Revenue | $129M |
| Cost Of Revenue | $89M |
| Costof Goods And Services Sold | $89M |
| Operating Income | -$17M |
| Selling General And Administrative | $44M |
| Research And Development | $8.3M |
| Operating Expenses | $58M |
| Investment Income Net | - |
| Net Interest Income | -$22M |
| Interest Income | - |
| Interest Expense | $22M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8M |
| Income Before Tax | -$39M |
| Income Tax Expense | $43K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$39M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$17M |
| Ebitda | -$8.8M |
| Net Income | -$39M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Lifecore Biomedical Inc. (LFCR) is a prominent integrated contract development and manufacturing organization based in Santa Maria, California, specializing in the formulation and production of complex biopharmaceuticals and medical devices. Utilizing cutting-edge technologies and robust industry experience, Lifecore delivers customized high-quality solutions to a wide array of clients globally. With a steadfast commitment to innovation and operational excellence, the company is well-positioned to address the dynamic demands of the biotechnology and healthcare sectors, making it an essential partner for organizations seeking to enhance their product portfolios and improve manufacturing efficiencies.